An observational study in Prostate Cancer, sponsored by Kansas State University. Completed at 1 site in United States. Open to male participants aged 21 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-02.
Sponsored by Kansas State University · Observational
The aim of this project is to determine whether androgen deprivation therapy (ADT) decreases left ventricular function in prostate cancer patients. If found successful, this may lead to improved cardiovascular health via treatment and/or lifestyle interventions in prostate cancer populations.
Prostate Cancer is the second most common cancer among American men. Approximately 1 in 7 men will be diagnosed with prostate cancer during his lifetime. In prostate cancer patients alone, hypotestosteronemia, caused by prostate cancer treatment is associated with visceral adiposity, insulin resistance, metabolic syndrome, decreased high-density lipoprotein, increased low-density lipoprotein, increased triglycerides, loss of muscle mass, erectile disfunction, and a loss of microvascular endothelial function. Recently, several population-based studies have reported an association between androgen deprivation therapy and an increased risk of cardiovascular events, that include myocardial infarction and cardiovascular mortality. Given this link and the growing evidence that androgen-deprivation therapy adversely affects traditional risk factors, it is essential to better understand the role this type of treatment has on cardiac structure and function. As such, the manifestation of cardiovascular toxicities with prostate cancer treatment will initially be subclinical (left ventricular function changes in asymptomatic individuals) compared to clinical (including coronary symptoms or heart failure) and may develop subacutely (during treatment) or chronically.
(Experimental Group #1) Diagnosed prostate cancer patients/survivors who have received androgen deprivation therapy, (Experimental Group #2) Diagnosed prostate cancer patients/survivors who have not received androgen deprivation therapy, and (Experimental Group #3) an aged matched, healthy control group.
Exclusion Criteria:
Prostate cancer patients or survivors who have a treatment history that includes androgen deprivation therapy. This includes 1) orchiectomy (surgical castration), 2) luteinizing hormone-releasing hormone (LHRH) agonists (also called LHRH analogs or Gonadotrophin-releasing hormone (GnRH) agonists), 3) LHRH antagonist, 4) CYP17 inhibitor, or 5) anti-androgen.
Diagnostic Test: Transthoracic Echocardiography · Diagnostic Test: Arterial blood pressure · Diagnostic Test: Submaximal Exercise
Prostate cancer patients or survivors who have never been treated with androgen deprivation therapy.
Diagnostic Test: Transthoracic Echocardiography · Diagnostic Test: Arterial blood pressure · Diagnostic Test: Submaximal Exercise
Individuals with no history of prostate caner androgen deprivation therapy. Free of known clinical cardiovascular disease
Diagnostic Test: Transthoracic Echocardiography · Diagnostic Test: Arterial blood pressure · Diagnostic Test: Submaximal Exercise
Non-invasive assessment of left ventricle structure and function
Continuously monitored for 5-30 minutes via finger photoplethysmography
Incremental exercise test to 85% predicted maximal heart rate on a recumbent cycle ergometer
Left ventricular ejection fraction
measure of left ventricular systolic function
Time frame: 1 day
Left ventricular strain rate
measure of left ventricular systolic and diastolic function
Time frame: 1 day
Cardiac output
measure of cardiac function at rest and during submaximal exercise
Time frame: 1 day
Plan to share: No
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kansas State University